PancellaPancella

Telephone

1-888-613-6862

Email Address

info@pancella.com

Office Address

1300-661 University Ave, Toronto

  • Home
  • About
    • Company Overview
      • Pluristyx
      • Implant Therapeutics
    • Management Team
    • Board of Directors
  • Technology
    • Origin
    • Core Technology
      • FailSafe®
    • Patents
    • Publications
  • Products & Licensing
    • Technology Licensing
  • News & Events
    • FAQ
    • Press Releases
CONTACT

Category Archives: Press Releases

Pancella   →  Blog   →  Press Releases

Pluristyx and panCELLa Expand Intellectual Property Portfolio for Pluripotent Stem Cell Cloaking Technology

Author By pancellaPosted on January 18, 2023January 18, 2023
panCELLa granted patent in the United Kingdom for induced Allogeneic Cell Tolerance (iACT Stealth™) Technology January 12, 2023 – Toronto – Pluristyx and panCELLa today are excited to announce the granting of a pa...

Pluristyx, panCELLa, and Implant Therapeutics Announce Definitive Merger Agreement

Author By pancellaPosted on October 6, 2022October 6, 2022
Fully integrated companies streamline access to genetically modified stem cells for clinical development   October 6, 2022 – Seattle, Washington - Today, Pluristyx, panCELLa, and Implant Therapeutics management...

Accelerating cell-based therapies by providing safe therapeutic MSC products

Author By pancellaPosted on January 7, 2021March 5, 2021
panCELLa’s intent to develop therapeutic products in the mesenchymal stem cell (MSC) and pancreatic islet space has recently led to the creation of Implant Therapeutics. Implant Therapeutics, under the guidance of D...

New iPSC Master Cell Banks to Accelerate Development of Novel Cell Therapies

Author By pancellaPosted on April 21, 2020March 5, 2021
New iPSC Master Cell Banks to Accelerate Development of Novel Cell Therapies panCELLa and CCRM collaborate to benefit academia and industry April 21, 2020, (Toronto, ON) -- Toronto-based panCELLa and CCRM have exec...

panCELLA receives research and development support for cell therapy

Author By pancellaPosted on April 7, 2020March 5, 2021
panCELLa is pleased to announce that it will receive advisory services and up to $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to help further research and develo...

panCELLa Extends Exclusive License to Astellas

Author By pancellaPosted on April 3, 2020March 5, 2021
panCELLa is pleased to announce that it has extended an exclusive license to Astellas for its proprietary cell technology addressing long-term allogeneic cell tolerance without the need for immune suppression of patients...

Evotec Expands Its IPSC-Based Cell Therapy Platform Evocells Through Licensing Agreement With Pancella

Author By pancellaPosted on April 2, 2020March 5, 2021
EVOTEC LICENSES PANCELLA’S STATE-OF-THE-ART IPSC TECHNOLOGies iACT STEALTH CELL™ AND FAILSAFE™ FOR USE IN CELL THERAPY ACCESS TO PANCELLA’S TECHNOLOGY HAS THE POTENTIAL TO ENABLE SAFE AND OFF-THE-SHELF CELL TH...

Cartherics and panCELLa announce collaborative agreement to develop pluripotent cell lines for cell therapy

Author By pancellaPosted on February 12, 2019March 5, 2021
Cartherics Pty Ltd ("Cartherics") and panCELLa Inc. ("panCELLa") are pleased to announce their collaboration to research, develop and commercialize products for the treatment of cancer and other debilitating diseases usi...
Nature

panCELLa’s Exclusive FailSafe Cells Improve Cell Therapy Safety

Author By pancellaPosted on November 14, 2018March 5, 2021
panCELLa is proud to announce the publication of “Linking a cell division and a suicide gene to define and improve cell therapy safety”  in the November 21st  2018 issue of Nature. Available online, you may view...
Pancella Logo

panCELLa Inc. raises $1M in seed funding

Author By pancellaPosted on January 24, 2018March 5, 2021
With the support of Chiefswood, panCELLa brings our exclusive FailSafe System to the market.  panCELLa offers a solution to the safety risks generally associated with cell therapies.  The exclusive "FailSafe Cell Syst...
panCELLa aims to make our therapeutic cell-focused Platform Technologies widely available for the treatment of degenerative, infectious and malignant diseases.

Useful Links

  • Company Overview
  • Board of Directors
  • Management Team
  • Careers
  • Contact

OUR SERVICES

  • Origin
  • Patents
  • Publications
  • Products & Licensing
  • Press Releases

RECENT POSTS

  • Pluristyx and panCELLa Expand Intellectual Property Portfolio for Pluripotent Stem Cell Cloaking Technology January 18, 2023
  • Pluristyx, panCELLa, and Implant Therapeutics Announce Definitive Merger Agreement October 6, 2022
  • panCELLa One Cell To Save A Million Others July 20, 2022
Copyright © 2023 PanCELLa. All rights reserved.